journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Haematology

journal
https://www.readbyqxmd.com/read/28083990/bkv-specific-t-cells-in-the-treatment-of-severe-refractory-haemorrhagic-cystitis-after-hla-haploidentical-haematopoietic-cell-transplantation
#1
Oscar M Pello, Andrew Innes, Anne Bradshaw, Sally-Anne Finn, Shab Uddin, Emma Bray, Eduardo Olavarria, Jane F Apperley, Jiri Pavlu
BACKGROUND: Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T-cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low frequency T-cells such as BKV-specific T-cells. CASE REPORT: Here we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy...
January 13, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28039906/prognostic-impact-of-cd5-expression-in-diffuse-large-b-cell-lymphoma-in-patients-treated-with-rituximab-epoch
#2
Beenu Thakral, L Jeffrey Medeiros, Parth Desai, Pei Lin, C Cameron Yin, Guilin Tang, Joseph D Khoury, Shimin Hu, Jie Xu, Sanam Loghavi, Bei Hu, Yasuhiro Oki, Shaoying Li
OBJECTIVES: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) represents 5-10% of all DLBCL cases, which has been associated with a poorer prognosis in patients treated with R-CHOP. Prognostic impact of CD5 expression in DLBCL patients treated with R-EPOCH has not been evaluated. METHODS: We studied 130 patients with de novo DLBCL who received frontline R-EPOCH therapy. The clinicopathologic features and overall survival (OS) were compared between the CD5+ and CD5-negative DLBCL patients...
December 31, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28009456/the-impact-of-socioeconomic-factors-on-treatment-choice-and-mortality-in-chronic-myeloid-leukaemia
#3
Gunnar Larfors, Fredrik Sandin, Johan Richter, Anders Själander, Leif Stenke, Mats Lambe, Martin Höglund
PURPOSE: To evaluate the influence of socioeconomic variables on treatment selection and survival of patients with chronic myeloid leukaemia (CML). METHODS: Using information available in population-based Swedish registries we evaluated indices of health, education and economy from the 980 patients in the Swedish CML register diagnosed between 2002 and 2012. Apart from internal comparisons, five age-, gender- and region-matched control subjects per patient served as control cohort...
December 23, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28009449/the-efficacy-and-safety-of-direct-oral-anticoagulants-vs-traditional-anticoagulants-in-cirrhosis
#4
Justine Hum, Joseph J Shatzel, Janice H Jou, Thomas G Deloughery
INTRODUCTION: The coagulopathy of cirrhosis is complex, placing patients at risk for both bleeding and thrombosis. Direct oral anticoagulants (DOACs) have equivalent or superior efficacy and safety as compared to vitamin K antagonists (VKA); however, their efficacy and safety in liver cirrhosis has not been studied. To better define this, we evaluated outcomes of cirrhotic patients prescribed DOACS compared to other anticoagulants at our center. METHODS: Retrospective cohort study of cirrhotic patients prescribed therapeutic anticoagulation over a 3 year period for thrombosis or prevention of stroke in patients with atrial fibrillation...
December 23, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28009447/modified-cvad-and-modified-cbad-compared-to-high-dose-cyclophosphamide-for-peripheral-blood-stem-cell-mobilization-in-patients-with-multiple-myeloma
#5
Suzanne C Gettys, Alison Gulbis, Kaci Wilhelm, Koji Sasaki, Yvonne Dinh, Gabriela Rondon, Muzaffar H Qazilbash
BACKGROUND: The optimal regimen for peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (auto-HCT) has not been established. Experience at The University of Texas MD Anderson Cancer Center suggests in addition to single-agent cyclophosphamide (Cy), modified cyclophosphamide, vincristine, doxorubicin and dexamethasone (mCVAD), and modified cyclophosphamide, bortezomib, doxorubicin and dexamethasone (mCBAD) may be successful chemomobilization regimens...
December 23, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28009442/predictive-factors-for-anemia-response-to-erythropoiesis-stimulating-agents-in-myelofibrosis
#6
Juan-Carlos Hernández-Boluda, Juan-Gonzalo Correa, Regina García-Delgado, Joaquín Martínez-López, Alberto Alvarez-Larrán, María-Laura Fox, Valentín García-Gutiérrez, Manuel Pérez-Encinas, Francisca Ferrer-Marín, María-Isabel Mata-Vázquez, José-María Raya, Natalia Estrada, Silvia García, Ana Kerguelen, María-Antonia Durán, Manuel Albors, Francisco Cervantes
Erythropoiesis stimulating agents (ESA) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited METHODS: Results of ESA therapy were analyzed in 163 MF patients with severe anemia, most of whom had inadequate erythropoietin (EPO) levels (< 125 U/l) at treatment start RESULTS: According to the revised criteria of the International Working Group for Myelofibrosis Treatment and Research, anemia response was achieved in 86 patients (53%). Median response duration was 19...
December 23, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28005278/igg4-related-disease-and-lymphocyte-variant-hypereosinophilic-syndrome-a-comparative-case-series
#7
Mollie N Carruthers, Sujin Park, Graham W Slack, Bakul I Dalal, Brian F Skinnider, David F Schaeffer, Jan P Dutz, Joanna K Law, Fergal Donnellan, Vladimir Marquez, Michael Seidman, Patrick C Wong, Andre Mattman, Luke Y C Chen
OBJECTIVE: To compare the clinical and laboratory features of IgG4-related disease (IgG4-RD) and lymphocyte variant-hypereosinophilic syndrome (L-HES), two rare diseases that often present with lymphadenopathy, gastrointestinal symptoms, eosinophilia and elevated immunoglobulins/IgE. METHOD: Comparative case series of 31 IgG4-RD and 13 L-HES patients. RESULTS: Peripheral blood eosinophilia was present in 8/31 IgG4-RD patients compared to 13/13 L-HES patients (median eosinophils 0...
December 22, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/28000291/the-role-of-flt3-inhibitors-in-the-treatment-of-flt3-mutated-acute-myeloid-leukemia
#8
REVIEW
Amir T Fathi, Yi-Bin Chen
FLT3 mutations are present in about one third of patients with AML. Several FLT3 inhibitors have been used in clinical trials and these include midostaurin, sorafenib, quizartinib, crenolanib and gilteritinib. Monotherapy with early TKIs did not have much success, however, later generation agents have shown more promising results. Combination with conventional chemotherapy may have benefit as evidenced by recently presented results, and data from ongoing trials are eagerly awaited. Several trials are also evaluating TKI given after HSCT and a large international randomized trial is planned...
December 21, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27992075/management-of-veno-occlusive-disease-the-multi-disciplinary-approach-to-care
#9
REVIEW
Elisabeth Wallhult, Michelle Kenyon, Sarah Liptrott, Arno Mank, Mairéad Ní Chonghaile, Aleksandra Babic, Jacobine Bijkerk, Caroline Bompoint, Selim Corbacioglu, Roel de Weijer, Claudia Fink, Sarah Marktel, Vivek Soni, Sarah Sprenger, Eugenia Trigoso Arjona, Mohamad Mohty
Although it is considered a relatively rare disorder, veno-occlusive disease (VOD) is one of the main causes of overall, non-relapse mortality associated with haematopoietic stem cell transplantation (HSCT). This article, based on the consensus opinion of haemato-oncology nurses, haemato-oncologists, and pharmacists from both adult and paediatric services at the VOD International Multi-Disciplinary Advisory Board at the European Society for Blood and Marrow Transplantation (EBMT) meeting, Istanbul, 2015, aims to explore the multi-disciplinary approach to care for the management of VOD, with an emphasis on current challenges in this area...
December 19, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27981682/rituximab-in-immune-thrombocytopenia-gender-age-and-response-as-predictors-of-long-term-response
#10
Miriam Marangon, Nicola Vianelli, Francesca Palandri, Maria Gabriella Mazzucconi, Cristina Santoro, Wilma Barcellini, Bruno Fattizzo, Stefano Volpetti, Elisa Lucchini, Nicola Polverelli, Monica Carpenedo, Miriam Isola, Renato Fanin, Francesco Zaja
OBJECTIVES: To evaluate the efficacy of a salvage treatment with Rituximab in adults with primary immune thrombocytopenia (ITP), in terms of short-term response and long-term response (LTR, i.e. probability to achieve and maintain response) and to identify biological and clinical predictors of response. METHODS: We retrospectively evaluated the outcome of patients with primary ITP treated with standard dosage RTX (375 mg/m(2) x 4) as salvage therapy in five Italian centres...
December 16, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27981643/ugt1a1-ta-n-genotype-is-not-the-major-risk-factor-of-cholelithiasis-in-sickle-cell-disease-children
#11
Philippe Joly, Céline Renoux, Philippe Lacan, Yves Bertrand, Giovanna Cannas, Nathalie Garnier, Daniella Cuzzubbo, Kamila Kebaïli, Cécile Renard, Alexandra Gauthier, Vincent Pialoux, Cyril Martin, Marc Romana, Philippe Connes
Because of the increased hemolytic rate, a significant proportion of patients with sickle cell disease (SCD) are prone to develop cholelithiasis. The present study investigated the role of several genetic factors (UGT1A1 promoter (TA)n repeat polymorphism, alpha-globin status), hematological parameters, clinical severity and hydroxyurea (HU) therapy on the occurrence of cholelithiasis in SCD METHODS: One hundred and fifty eight children (2-18 years old) and regularly followed at the university hospital of Lyon (France) were included...
December 16, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27943422/pretransplant-fdg-pet-in-aggressive-non-hodgkin-lymphoma-systematic-review-and-meta-analysis
#12
REVIEW
Hugo J A Adams, Thomas C Kwee
This study aimed to systematically review and meta-analyze the value of pretransplant FDG-PET in predicting outcome after autologous stem cell transplantation (ASCT) in aggressive non-Hodgkin lymphoma. Medline was systematically searched, included studies were methodologically assessed and meta-analyzed, when possible. Overall methodological quality of included studies (n=11) was poor, with moderate risk of bias in the domains of study participation (n=7) and prognostic factor measurement (n=7), and high risk of bias in the domains of outcome measurement (n=10), and study confounding (n=11)...
December 10, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27943415/flow-cytometry-minimal-residual-disease-after-allogeneic-transplant-for-chronic-lymphocytic-leukemia
#13
Caroline Algrin, Jean-Louis Golmard, Mauricette Michallet, Oumedaly Reman, Anne Huynh, Aurore Perrot, Anne Sirvent, Adriana Plesa, Véronique Salaun, Marie-Christine Béné, Dominique Bories, Olivier Tournilhac, Hélène Merle-Béral, Véronique Leblond, Magali LeGarff-Tavernier, Nathalie Dhedin
OBJECTIVES: This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome. METHODS: We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry. RESULTS: At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response and 11% had refractory disease...
December 10, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27893172/anthropometrics-and-prognosis-in-diffuse-large-b-cell-lymphoma-a-multicentre-study-of-653-patients
#14
Mette Dahl Bendtsen, Peter Svenssen Munksgaard, Marianne Tang Severinsen, Eric Bekric, Christian Brieghel, Kristina Buchardi Nielsen, Peter de Nully Brown, Karen Dybkaer, Hans Erik Johnsen, Martin Bøgsted, Tarec Christoffer El-Galaly
OBJECTIVE: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. PATIENTS AND METHODS: 653 R-CHOP(-like) treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27893171/salvage-therapy-in-first-relapse-a-retrospective-study-in-a-large-patient-population-with-multiple-myeloma
#15
Massimo Offidani, Laura Corvatta, Sara Bringhen, Silvia Gentili, Rossella Troia, Laura Maracci, Alessandra Larocca, Francesca Gay, Pietro Leoni, Mario Boccadoro
OBJECTIVE: There is no strong evidence to guide therapeutic approach to multiple myeloma (MM) patients who experience first relapse. The treatment choice can be difficult since currently all patients are exposed to novel agents as thalidomide, bortezomib and lenalidomide. METHODS: In this retrospective analysis, we evaluated the best therapeutic sequence, the role of retreatment, and the most beneficial cutoff of first remission in order to choose retreatment, analyzing 476 patients relapsed after first-line therapy...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27893170/safety-profiles-of-iron-chelators-in-young-patients-with-haemoglobinopathies
#16
REVIEW
Sebastian Botzenhardt, Niya Li, Esther W Chan, Chor Wing Sing, Ian C K Wong, Antje Neubert
BACKGROUND: This review describes the safety of deferoxamine (DFO), deferiprone (DFP), deferasirox (DFX), and combined therapy in young patients less than 25 years of age with haemoglobinopathies. METHOD: Searches in electronic literature databases were performed. Studies reporting adverse events associated with iron chelation therapy were included. Study and reporting quality was assessed using AHRQ Risk of Bias Assessment Tool and McMaster Quality Assessment Scale of Harms...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27893163/sorafenib-and-azacitidine-as-salvage-therapy-for-relapse-of-flt3-itd-mutated-aml-after-allo-sct
#17
Christina Rautenberg, Kathrin Nachtkamp, Ariane Dienst, Pia Verena Schmidt, Claudia Heyn, Mustafa Kondakci, Ulrich Germing, Rainer Haas, Guido Kobbe, Thomas Schroeder
OBJECTIVE: Patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations (FLT3-ITD+) who relapse after allogeneic 3transplantation (allo-SCT) have a very dismal prognosis with the currently available treatment options. METHODS: We treated 8 patients with FLT3-ITD+ AML who had relapsed in median 91 days (range, 28 - 249) following allo-SCT with a combination of the multikinase inhibitor Sorafenib and the DNA methyltransferase inhibitor Azacitidine (Aza)...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27859681/familial-acquired-thrombotic-thrombocytopenic-purpura-in-siblings-no-immunogenetic-link-with-associated-human-leucocyte-antigens
#18
Philipp Gödel, Julia Fischer, Christoph Scheid, Birgit S Gathof, Jürgen Wolf, Jan Rybniker
Acquired immunoglobulin G (IgG)-mediated thrombotic thrombocytopenic purpura (TTP) has not yet been described in non-twin siblings. We report two cases of acquired TTP in Caucasian sisters with inactive ADAMTS13 metalloprotease due to ADAMTS13 autoantibodies suggesting a role of genetic determinants in this life-threatening disease. However, human leucocyte antigen (HLA) class II types presumably associated with acquired TTP were not identified in the patients, indicating that HLA class II typing may not be useful in acquired TTP risk assessment of family members...
November 18, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27859648/limitations-of-serum-ferritin-to-predict-liver-iron-concentration-responses-to-deferasirox-therapy-in-patients-with-transfusion-dependent-thalassemia
#19
John B Porter, Mohsen Elalfy, Ali Taher, Yesim Aydinok, Szu-Hee Lee, Pranee Sutcharitchan, Ali El-Ali, Jackie Han, Amal El-Beshlawy
BACKGROUND: In transfusion-dependent anaemias, while absolute serum ferritin levels broadly correlate with liver iron concentration (LIC), relationships between trends in these variables are unclear. These relationships are important because serum ferritin changes are often used to adjust or switch chelation regimens when liver magnetic resonance imaging (MRI) is unavailable. OBJECTIVES AND METHODS: This post-hoc analysis of the EPIC study compared serum ferritin and LIC in 317 patients with transfusion-dependent thalassaemia before and after 1 year of deferasirox...
November 17, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27859769/association-between-complete-response-and-outcomes-in-transplant-eligible-myeloma-patients-in-the-era-of-novel-agents
#20
Helgi van de Velde, Anil Londhe, Ozlem Ataman, Helen L Johns, Stephen Hill, Emma Landers, Jesse A Berlin
OBJECTIVES: Achieving complete response (CR) has been linked to improved progression-free (PFS) and overall (OS) survival in myeloma. A meta-analysis was conducted to investigate whether this holds true in the era of novel agents (bortezomib, lenalidomide, thalidomide). METHODS: A total of 24 studies in newly diagnosed patients undergoing autologous stem cell transplantation (ASCT) that reported associations between responses and long-term outcomes (PFS/OS rates post-ASCT by response, or hazard ratios with 95% confidence intervals from Cox models) were identified and analyzed...
November 16, 2016: European Journal of Haematology
journal
journal
29503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"